Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 279

The DOI matches its Crossref record; 142 of the 142 references it cites were found in a registry or an index.

Disease-modifying therapies for Alzheimer disease: Challenges to early intervention

Cummings, Jeffrey L., Doody, Rachelle, Clark, Christopher·2007·Neurology

Abstract

Prevention of Alzheimer disease (AD) is a national and global imperative. Therapy is optimally initiated when individuals are asymptomatic or exhibit mild cognitive impairment (MCI). Development of therapeutically beneficial compounds requires the creation of clinical trial methodologies for primary and secondary prevention. Populations in primary prevention trials selected only on the basis of age will have low rates of emergent MCI or AD. Epidemiologically based risk factors or biomarkers can be used to enrich trials and increase the likelihood of disease occurrence during the trial. Enrichment strategies for clinical trials with MCI include use of biomarkers such as amyloid imaging, MRI with demonstration of medial temporal lobe atrophy, bilateral parietal hypometabolism on PET, and reduced amyloid beta peptide and increased tau protein in CSF. Neuropsychological measures appropriate for trials of MCI may not be identical to those measures most suited for AD trials. Attention to these and other features of trial design, clinical assessment, and use of biomarkers is critical to improving the detection of disease-modifying effects of emerging therapies in presymptomatic or minimally symptomatic populations. The neurologic health of the growing aging population demands disease-modifying therapies and the development of methods to identify and test promising candidate agents. GLOSSARY: AD = Alzheimer disease; ADAPT = Alzheimer’s Disease Anti-inflammatory Prevention Trial; ADAS-cog = Alzheimer’s Disease Assessment Scale–Cognitive subscale; ADCS = Alzheimer’s Disease Cooperative Study; FDG = fluorodeoxyglucose; GSK = glycogen synthase kinase; MCI = mild cognitive impairment; NAA = N-acetylaspartate; PPAR = peroxisome proliferator-activated receptor.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/01.wnl.0000295996.54210.69

Cites

142 of 142 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 142 references

Cited by

See all 279

Metadata

Authors
Cummings, J. L., Doody, R., & Clark, C.
Venue
Neurology
Published
2007-10-16
Volume
69
Issue
16
Pages
1622-1634
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2015514982
Cited by
279
References
142
FWCI
15.29
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Disease-modifying therapies for Alzheimer disease: Challenges to early intervention. https://app.cochat.ai/papers/10.1212/01.wnl.0000295996.54210.69
The paper
Cummings, J. L., Doody, R., & Clark, C. (2007). Disease-modifying therapies for Alzheimer disease: Challenges to early intervention. Neurology. https://doi.org/10.1212/01.wnl.0000295996.54210.69

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.